Management of comorbid diabetes and cancer
Diabetes mellitus is a frequent comorbidity of cancer patients. The growing epidemic of diabetes is anticipated to have tremendous impact on health care. Diabetes may negatively impact both cancer risk and outcomes of treatment. Oncology nurses are ideally positioned to identify patients at risk for...
Gespeichert in:
| Veröffentlicht in: | Oncology (Williston Park, N.Y.) N.Y.), 2007-07, Vol.21 (8 Suppl), p.26 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 Suppl |
| container_start_page | 26 |
| container_title | Oncology (Williston Park, N.Y.) |
| container_volume | 21 |
| creator | Singer, Marybeth |
| description | Diabetes mellitus is a frequent comorbidity of cancer patients. The growing epidemic of diabetes is anticipated to have tremendous impact on health care. Diabetes may negatively impact both cancer risk and outcomes of treatment. Oncology nurses are ideally positioned to identify patients at risk for complications that arise from cancer treatment in the setting of pre-existing diabetes. Additionally, oncology nurses may be the first to identify underlying hyperglycemia/hidden diabetes in a patient undergoing cancer treatment. Strategies for assessment and treatment will be discussed, along with specific strategies for managing hyperglycemia, potential renal toxicity, and peripheral neuropathy. Guidelines for aggressive treatment of hyperglycemia to minimize risks of complications will be reviewed. The role of interdisciplinary care, utilizing current evidence, is crucial to supporting patients and their families as they manage the challenges of facing two life-limiting diseases. Whole-person assessment and individualized treatment plans are key to maximizing quality of life for patients with cancer and diabetes. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_195446820</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1455554741</sourcerecordid><originalsourceid>FETCH-LOGICAL-p151t-6998786219909217e4067519f6fafb84f40efaadbd06c0c0941f21af658e4d293</originalsourceid><addsrcrecordid>eNo1j0tLxDAURrNQnHH0L0hwKRRu0jTNXcrgC0bc6LrcJDfSwT5M24X_3oLj6tscvsM5E1twCAUCqo24nKYjgLYW3IXYqNoZ47DcirtX6umTO-5nOSQZhm7Ivo0ytuR55klSH2WgPnC-EueJvia-Pu1OfDw-vO-fi8Pb08v-_lCMqlJzYRFd7axWuJq1qtmArSuFySZK3plkgBNR9BFsgABoVNKKkq0cm6ix3Inbv98xD98LT3NzHJbcr8pGYWWMdRpW6OYELb7j2Iy57Sj_NP9l5S_dK0bT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195446820</pqid></control><display><type>article</type><title>Management of comorbid diabetes and cancer</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Singer, Marybeth</creator><creatorcontrib>Singer, Marybeth</creatorcontrib><description>Diabetes mellitus is a frequent comorbidity of cancer patients. The growing epidemic of diabetes is anticipated to have tremendous impact on health care. Diabetes may negatively impact both cancer risk and outcomes of treatment. Oncology nurses are ideally positioned to identify patients at risk for complications that arise from cancer treatment in the setting of pre-existing diabetes. Additionally, oncology nurses may be the first to identify underlying hyperglycemia/hidden diabetes in a patient undergoing cancer treatment. Strategies for assessment and treatment will be discussed, along with specific strategies for managing hyperglycemia, potential renal toxicity, and peripheral neuropathy. Guidelines for aggressive treatment of hyperglycemia to minimize risks of complications will be reviewed. The role of interdisciplinary care, utilizing current evidence, is crucial to supporting patients and their families as they manage the challenges of facing two life-limiting diseases. Whole-person assessment and individualized treatment plans are key to maximizing quality of life for patients with cancer and diabetes.</description><identifier>ISSN: 0890-9091</identifier><identifier>PMID: 17844893</identifier><language>eng</language><publisher>United States: MultiMedia Healthcare Inc</publisher><subject>Ambulatory Care ; Amyloid - therapeutic use ; Comorbidity ; Diabetes Mellitus - classification ; Diabetes Mellitus - diagnosis ; Diabetes Mellitus - epidemiology ; Diabetes Mellitus - physiopathology ; Diabetes Mellitus - therapy ; Humans ; Hypoglycemic Agents - therapeutic use ; Inpatients ; Insulin - therapeutic use ; Islet Amyloid Polypeptide ; Neoplasms - complications ; Neoplasms - epidemiology ; Neoplasms - therapy ; Peptides - therapeutic use ; Practice Guidelines as Topic ; Pyrazines - therapeutic use ; Quality of Life ; Risk Factors ; Sitagliptin Phosphate ; Treatment Outcome ; Triazoles - therapeutic use ; Venoms - therapeutic use</subject><ispartof>Oncology (Williston Park, N.Y.), 2007-07, Vol.21 (8 Suppl), p.26</ispartof><rights>Copyright CMP Media LLC Jul 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17844893$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singer, Marybeth</creatorcontrib><title>Management of comorbid diabetes and cancer</title><title>Oncology (Williston Park, N.Y.)</title><addtitle>Oncology (Williston Park)</addtitle><description>Diabetes mellitus is a frequent comorbidity of cancer patients. The growing epidemic of diabetes is anticipated to have tremendous impact on health care. Diabetes may negatively impact both cancer risk and outcomes of treatment. Oncology nurses are ideally positioned to identify patients at risk for complications that arise from cancer treatment in the setting of pre-existing diabetes. Additionally, oncology nurses may be the first to identify underlying hyperglycemia/hidden diabetes in a patient undergoing cancer treatment. Strategies for assessment and treatment will be discussed, along with specific strategies for managing hyperglycemia, potential renal toxicity, and peripheral neuropathy. Guidelines for aggressive treatment of hyperglycemia to minimize risks of complications will be reviewed. The role of interdisciplinary care, utilizing current evidence, is crucial to supporting patients and their families as they manage the challenges of facing two life-limiting diseases. Whole-person assessment and individualized treatment plans are key to maximizing quality of life for patients with cancer and diabetes.</description><subject>Ambulatory Care</subject><subject>Amyloid - therapeutic use</subject><subject>Comorbidity</subject><subject>Diabetes Mellitus - classification</subject><subject>Diabetes Mellitus - diagnosis</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Diabetes Mellitus - physiopathology</subject><subject>Diabetes Mellitus - therapy</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Inpatients</subject><subject>Insulin - therapeutic use</subject><subject>Islet Amyloid Polypeptide</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - epidemiology</subject><subject>Neoplasms - therapy</subject><subject>Peptides - therapeutic use</subject><subject>Practice Guidelines as Topic</subject><subject>Pyrazines - therapeutic use</subject><subject>Quality of Life</subject><subject>Risk Factors</subject><subject>Sitagliptin Phosphate</subject><subject>Treatment Outcome</subject><subject>Triazoles - therapeutic use</subject><subject>Venoms - therapeutic use</subject><issn>0890-9091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNo1j0tLxDAURrNQnHH0L0hwKRRu0jTNXcrgC0bc6LrcJDfSwT5M24X_3oLj6tscvsM5E1twCAUCqo24nKYjgLYW3IXYqNoZ47DcirtX6umTO-5nOSQZhm7Ivo0ytuR55klSH2WgPnC-EueJvia-Pu1OfDw-vO-fi8Pb08v-_lCMqlJzYRFd7axWuJq1qtmArSuFySZK3plkgBNR9BFsgABoVNKKkq0cm6ix3Inbv98xD98LT3NzHJbcr8pGYWWMdRpW6OYELb7j2Iy57Sj_NP9l5S_dK0bT</recordid><startdate>200707</startdate><enddate>200707</enddate><creator>Singer, Marybeth</creator><general>MultiMedia Healthcare Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200707</creationdate><title>Management of comorbid diabetes and cancer</title><author>Singer, Marybeth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p151t-6998786219909217e4067519f6fafb84f40efaadbd06c0c0941f21af658e4d293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Ambulatory Care</topic><topic>Amyloid - therapeutic use</topic><topic>Comorbidity</topic><topic>Diabetes Mellitus - classification</topic><topic>Diabetes Mellitus - diagnosis</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Diabetes Mellitus - physiopathology</topic><topic>Diabetes Mellitus - therapy</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Inpatients</topic><topic>Insulin - therapeutic use</topic><topic>Islet Amyloid Polypeptide</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - epidemiology</topic><topic>Neoplasms - therapy</topic><topic>Peptides - therapeutic use</topic><topic>Practice Guidelines as Topic</topic><topic>Pyrazines - therapeutic use</topic><topic>Quality of Life</topic><topic>Risk Factors</topic><topic>Sitagliptin Phosphate</topic><topic>Treatment Outcome</topic><topic>Triazoles - therapeutic use</topic><topic>Venoms - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singer, Marybeth</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Oncology (Williston Park, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singer, Marybeth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of comorbid diabetes and cancer</atitle><jtitle>Oncology (Williston Park, N.Y.)</jtitle><addtitle>Oncology (Williston Park)</addtitle><date>2007-07</date><risdate>2007</risdate><volume>21</volume><issue>8 Suppl</issue><spage>26</spage><pages>26-</pages><issn>0890-9091</issn><abstract>Diabetes mellitus is a frequent comorbidity of cancer patients. The growing epidemic of diabetes is anticipated to have tremendous impact on health care. Diabetes may negatively impact both cancer risk and outcomes of treatment. Oncology nurses are ideally positioned to identify patients at risk for complications that arise from cancer treatment in the setting of pre-existing diabetes. Additionally, oncology nurses may be the first to identify underlying hyperglycemia/hidden diabetes in a patient undergoing cancer treatment. Strategies for assessment and treatment will be discussed, along with specific strategies for managing hyperglycemia, potential renal toxicity, and peripheral neuropathy. Guidelines for aggressive treatment of hyperglycemia to minimize risks of complications will be reviewed. The role of interdisciplinary care, utilizing current evidence, is crucial to supporting patients and their families as they manage the challenges of facing two life-limiting diseases. Whole-person assessment and individualized treatment plans are key to maximizing quality of life for patients with cancer and diabetes.</abstract><cop>United States</cop><pub>MultiMedia Healthcare Inc</pub><pmid>17844893</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0890-9091 |
| ispartof | Oncology (Williston Park, N.Y.), 2007-07, Vol.21 (8 Suppl), p.26 |
| issn | 0890-9091 |
| language | eng |
| recordid | cdi_proquest_journals_195446820 |
| source | MEDLINE; EZB Electronic Journals Library |
| subjects | Ambulatory Care Amyloid - therapeutic use Comorbidity Diabetes Mellitus - classification Diabetes Mellitus - diagnosis Diabetes Mellitus - epidemiology Diabetes Mellitus - physiopathology Diabetes Mellitus - therapy Humans Hypoglycemic Agents - therapeutic use Inpatients Insulin - therapeutic use Islet Amyloid Polypeptide Neoplasms - complications Neoplasms - epidemiology Neoplasms - therapy Peptides - therapeutic use Practice Guidelines as Topic Pyrazines - therapeutic use Quality of Life Risk Factors Sitagliptin Phosphate Treatment Outcome Triazoles - therapeutic use Venoms - therapeutic use |
| title | Management of comorbid diabetes and cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T20%3A52%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20comorbid%20diabetes%20and%20cancer&rft.jtitle=Oncology%20(Williston%20Park,%20N.Y.)&rft.au=Singer,%20Marybeth&rft.date=2007-07&rft.volume=21&rft.issue=8%20Suppl&rft.spage=26&rft.pages=26-&rft.issn=0890-9091&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1455554741%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195446820&rft_id=info:pmid/17844893&rfr_iscdi=true |